Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

摘要: OBJECTIVES To describe the microbiology and antimicrobial resistance patterns of cultured samples acquired from Canadian ICUs. METHODS From 2007 to 2016, tertiary care centres across Canada submitted 42938 bacterial/fungal isolates as part CANWARD surveillance study. Of these, 8130 (18.9%) were patients on Susceptibility testing guidelines MIC interpretive criteria defined by CLSI. RESULTS pathogens collected in this study, 58.2%, 36.3%, 3.1% 2.4% respiratory, blood, wound urine specimens, respectively. The top five organisms ICUs accounted for 55.4% all included Staphylococcus aureus (21.5%), Pseudomonas aeruginosa (10.6%), Escherichia coli (10.4%), Streptococcus pneumoniae (6.5%) Klebsiella (6.4%). MRSA 20.7% S. collected, with community-associated (CA) genotypes increasing prevalence over time (P < 0.001). highest susceptibility rates among 100% vancomycin, ceftobiprole, linezolid, 99.7% ceftaroline, daptomycin tigecycline. E. tigecycline, 99.9% meropenem, colistin 94.2% piperacillin/tazobactam. MDR was identified 26.3% isolates, 10.1% producing an ESBL. P. 97.5% ceftolozane/tazobactam, 96.1% amikacin, 94.7% 93.3% tobramycin. CONCLUSIONS most active agents against Gram-negative bacilli carbapenems, tigecycline Against Gram-positive cocci, linezolid. CA-MRSA ESBL-producing increased significantly time.